Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLG1091 vs Rybelsus as Add-on to Metformin in Type 2 Diabetes
NCT07487103Phase 3Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2026
- Primary completion
- Dec 2026
- Modality
- Peptides
01
Overview
A Phase 3 trial of QLG1091 in type 2 diabetes mellitus (T2DM), sponsored by Qilu Pharmaceutical. Planned start May 2026; status: not yet recruiting.
02
Drugs
QLG1091
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07487103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07487103.